Insmed Inc. (INSM) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Insmed Inc. (INSM)

INSM 186.34

-1.7%

Nov 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SemiBull who wrote (19)	7/9/2002 10:04:01 AM
From: mopgcw	Read Replies (1) of 136

caught bits and pieces of the conference call update: made tremendous progress in somatokine manufacturing in quantity and cost effectiveness. initiated studies in gowth hormone insensitivity syndrome (ghis). orphan status, begin in 2003. BP3 demonstrated anti-tumor properties in animal models, significant preclinical program underway. 1/03 clinical trials to begin. clinical grade manufacturing end of this year. nothing fundamental has changed. wait and see results of ongoing studies. key hiring decisions made, will be adding more. Randy W and LA Times story - non-issue.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next